On Monday it outlined why it thinks its business is largely shielded.Biotechnology giant CSL argues an ageing population will help shield its business from any falloutweight loss, and potentially undermining its investment in therapies targeting kidney disease.
The plans were outlined at an investor day for CSL, a $116 billion company that is one of Australia’s big biotechnology growth stories, evolving from a government-owned enterprise established in 1916 to having 30,000 staff delivering products in more than 100 countries.with margins in blood collection centres under pressure and rivals planning to launch generic drugs against its iron deficiency product, Ferinject.
CSL head of research and development Bill Mezzanotte maintained the patients in the trial only represented a “small percentage of the overall dialysis patient population, which of course is only a small percentage of the business”. “However, offset by that, GLP-1s will do nothing for ageing,” he said. “And the overall population remains to continue to age, and that will likely balance the effect and keep the number of in total, relatively constant.”
Portugal Últimas Notícias, Portugal Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: theage - 🏆 8. / 77 Consulte Mais informação »
Fonte: brisbanetimes - 🏆 13. / 67 Consulte Mais informação »